"The US Food and Drug Administration (FDA) has approved atazanavir and cobicistat (Evotaz, Bristol-Myers Squibb) for treatment of adults with human immunodeficiency virus (HIV-1) infection.
Atazanavir/cobicistat is a fixed-dos"...
Human experience of acute overdose with RESCRIPTOR is limited.
Management of Overdosage
Treatment of overdosage with RESCRIPTOR should consist of general supportive measures, including monitoring of vital signs and observation of the patient's clinical status. There is no specific antidote for overdosage with RESCRIPTOR. If indicated, elimination of unabsorbed drug should be achieved by emesis or gastric lavage. Since delavirdine is extensively metabolized by the liver and is highly protein-bound, dialysis is unlikely to result in significant removal of the drug.
RESCRIPTOR Tablets are contraindicated in patients with known hypersensitivity to any of its ingredients. Coadministration of RESCRIPTOR is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events. These drugs are listed in Table 5. Also, see PRECAUTIONS, Table 6, Drugs That Should Not Be Coadministered With RESCRIPTOR.
Table 5: Drugs That Are Contraindicated With RESCRIPTOR
|Drug Class||Drugs Within Class That Are Contraindicated With RESCRIPTOR|
|Ergot derivatives||Dihydroergotamine, ergonovine, ergotamine, methylergonovine|
|GI motility agent||Cisapride|
|Sedative/hypnotics||Alprazolam, midazolam, triazolam|
Last reviewed on RxList: 8/29/2012
Additional Rescriptor Information
Rescriptor - User Reviews
Rescriptor User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get breaking medical news.